ABD - İngilizce - NLM (National Library of Medicine)

amorepacific - titanium dioxide 9.31%, zinc oxide 2.94% -

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - interferon beta-1a, quantity: 88 microgram/ml - injection, solution - excipient ingredients: benzyl alcohol; water for injections; sodium hydroxide; acetic acid; methionine; poloxamer; mannitol - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - interferon beta-1a, quantity: 44 microgram/ml - injection, solution - excipient ingredients: sodium hydroxide; poloxamer; benzyl alcohol; methionine; acetic acid; water for injections; mannitol - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - methotrexate, quantity: 5000 mg - injection, concentrated - excipient ingredients: sodium hydroxide; water for injections - antineoplastic chemotherapy:,methotrexate has a broad spectrum of antineoplastic activity. it is indicated for the treatment of breast cancer and the palliation of acute and subacute lymphocytic leukaemia (greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias). methotrexate is now most commonly used for the maintenance of drug induced remissions.,high dose therapy:,in high dose schedules, methotrexate may be effective alone or in combination therapy, in the treatment of epidermoid cancers of the head and neck, osteogenic sarcoma and bronchogenic sarcoma. calcium folinate (leucovorin calcium) must be used in conjunction with high dose methotrexate therapy.,psoriasis chemotherapy (see warnings box and section 4.4 special warnings and precautions for use).:,methotrexate may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after diagnosis has been definitely established , as by biopsy and/or after dermatological consultation.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

biogen australia pty ltd - interferon beta-1a, quantity: 60 microgram/ml - injection, solution - excipient ingredients: polysorbate 20; glacial acetic acid; sodium acetate; water for injections; arginine hydrochloride - avonex is indicated for the treatment of patients with relapsing forms of multiple sclerosis (ms). avonex is indicated in patients who have experienced a single demyelinating event and are at risk of developing clinically definite ms based on the presence of brain mri abnormalities characteristic of ms. avonex 60 mcg is indicated for the treatment of secondary progressive ms in patients in whom relapse is still a feature of disease. avonex 60 mcg should not be initiated in patients with secondary progressive ms who have not experienced relapse in the previous 12 months.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - interferon beta-1a, quantity: 88 microgram/ml - injection, solution - excipient ingredients: benzyl alcohol; water for injections; sodium hydroxide; acetic acid; methionine; poloxamer; mannitol - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - interferon beta-1a, quantity: 44 microgram/ml - injection, solution - excipient ingredients: sodium hydroxide; poloxamer; benzyl alcohol; methionine; acetic acid; water for injections; mannitol - rebif is indicated for the treatment of: ? patients with a single demyelinating event in the central nervous system with an active inflammatory process, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis. high risk can be inferred from cerebral mri with 2 or more lesions suggestive of demyelination.,? ambulatory patients with multiple sclerosis who have experienced two or more relapses within the last 2 years. rebif therapy should not be initiated in secondary progressive ms patients who no longer experience relapses.?

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - methotrexate, quantity: 1000 mg - injection, concentrated - excipient ingredients: sodium hydroxide; water for injections - antineoplastic chemotherapy:,methotrexate has a broad spectrum of antineoplastic activity. it is indicated for the treatment of breast cancer and the palliation of acute and subacute lymphocytic leukaemia (greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias). methotrexate is now most commonly used for the maintenance of drug induced remissions.,high dose therapy:,in high dose schedules, methotrexate may be effective alone or in combination therapy, in the treatment of epidermoid cancers of the head and neck, osteogenic sarcoma and bronchogenic sarcoma. calcium folinate (leucovorin calcium) must be used in conjunction with high dose methotrexate therapy.,psoriasis chemotherapy (see warnings box and section 4.4 special warnings and precautions for use):,methotrexate may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after diagnosis has been definitely established , as by biopsy and/or after dermatological consultation.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - methotrexate, quantity: 500 mg - injection, concentrated - excipient ingredients: water for injections; sodium hydroxide - antineoplastic chemotherapy:,methotrexate has a broad spectrum of antineoplastic activity. it is indicated for the treatment of breast cancer and the palliation of acute and subacute lymphocytic leukaemia (greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukaemias). methotrexate is now most commonly used for the maintenance of drug induced remissions.,high dose therapy:,in high dose schedules, methotrexate may be effective alone or in combination therapy, in the treatment of epidermoid cancers of the head and neck, osteogenic sarcoma and bronchogenic sarcoma. calcium folinate (leucovorin calcium) must be used in conjunction with high dose methotrexate therapy.,psoriasis chemotherapy (see warnings box and section 4.4 special warnings and precautions for use):,methotrexate may be of value in the symptomatic control of severe, recalcitrant, disabling psoriasis that is not adequately responsive to other forms of treatment. however, due to the high risk associated with its use, methotrexate should be used after diagnosis has been definitely established , as by biopsy and/or after dermatological consultation.

Avustralya - İngilizce - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - metoprolol tartrate, quantity: 50 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; hyprolose; calcium hydrogen phosphate dihydrate; crospovidone - hypertension; angina pectoris; suspected or definite myocardial infarction; migraine prophylaxis